Abstract Introduction: Patients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls. Objective: To evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques. Methods: Cross-sectional study in patients with SLE. A metabolomic approach was employed using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry. MetS was evaluated according to NCEP-ATP III criteria. Results: Seventy patients with SLE were included, out of whom 45 (64.2 %) and 27 (38.5 %) had IR and MetS, respectively. Patients with IR had a higher body mass index and hypertension more often than those without IR. Chronic damage and disease activity were not related to IR. A Quantose-IR score ≥ 63 was more common in patients with MetS (81.5 vs. 53.5 %; p = 0.02). Quantose-IR score was also correlated with the number of criteria for MetS (r: 0.35; p = 0.003). Conclusions: In non-diabetic women with SLE, the prevalence of IR based on Quantose-IR score was 64.2 %.

Resumen Introducción: En lupus eritematoso sistémico (LES) es más frecuente la prevalencia de resistencia a la insulina (RI) y síndrome metabólico (SMet) que en controles. Objetivo: Evaluar la RI en mujeres no diabéticas con LES mediante biomarcadores usando técnicas metabolómicas de alta resolución. Método: Estudio transversal en pacientes con LES. Se empleó un abordaje metabolómico usando cromatografía de líquidos de ultra-alta resolución con espectrometría de masa de alta resolución. El SMet fue evaluado de acuerdo con los criterios NCEP-ATP III. Resultados: Se incluyeron 70 pacientes con LES. Tuvieron RI y SMet 45 (64.2%) y 27 (38.5%), respectivamente. Pacientes con RI tenían un mayor índice de masa corporal e hipertensión con mayor frecuencia que aquellas sin RI. El daño crónico y la actividad de la enfermedad no se relacionaron con RI. Un puntaje de Quantose RI ≥ 63 fue más elevado en pacientes con SMet (81.5 vs 53.5%; p = 0.02). El puntaje Quantose RI también se correlacionó con el número de criterios para SMet (r: 0.35; p = 0.003). Conclusiones: En mujeres con LES no diabéticas, la prevalencia de RI basada en el puntaje de Quantose RI fue del 64.2%.

Bond failures are produced by the existence of biofilm on the tooth surface. Because biofilm is impermeable, it prevents contact in many areas, reducing the etching effect which selectively dissolves calcified tissues but does not seem to eliminate biofilm from the tooth surface, and thus the bond between the tooth and the bracket is not strong enough. The aim of this study is to compare bracket bonding efficiency with two dental surface pretreatments: sodium hypochlorite vs. hydrogen peroxide techniques. This was a cross-sectional, comparative, in vitro study. Seventy-five premolars extracted for orthodontic purposes were evaluated. They were divided into three groups of 25 teeth and assigned randomly toone of the pretreatment techniques (5.25%sodium hypochlorite or 3.5% hydrogen peroxide) or to a control group. The most efficient pretreatment technique for bonding to brackets was sodium hypochlorite, with an average of 17.15 (kg/F). Significant differences were observed between groups (p=0.0001). The post hoc bond strength test showed statistically significant differences between the sodium hypochlorite technique and the control group (p=0.0001). The sodium hypochlorite technique improves bracket adhesion to tooth enamel.

Las fallas de adhesion se producen por la existencia de la biopelicula en la superficie del organo dental, ya que es impermeable y no permite el contacto en muchas areas, de manera que disminuye el efecto del grabado acido; el cual tiene la capacidad de disolver selectivamente los tejidos calcificados, pero no parece eliminar la biopelicula en la superficie dental, por lo tanto, no se lleva a cabo la suficiente fuerza de adhesion en la interfase diente-bracket. El objetivo es comparar la eficiencia en la adhesion de los brackets con el empleo de dos metodos de pre-tratamientos de la superficie del esmalte, el hipoclorito de sodio vs. peroxido de hidrogeno. Estudio comparativo, transversal, in vitro. Se evaluaron 75 premolares extraidos con fines ortodoncicos, tres grupos de 25 dientes, asignados aleatoriamente con alguna de las dos tecnicas de pre-tratamiento al esmalte, hipoclorito de sodio al 5.25%, peroxido de hidrogeno al 3.5% y un grupo control. La tecnica de pre-tratamiento al esmalte mas eficiente para la fuerza de adhesion a los brackets fue el hipoclorito de sodio, con una media de 17.15 (Kg/F), se observaron diferencias significativas inter-grupos (p= 0.001). Las pruebas post hoc para las fuerzas de adhesion mostraron diferencia estadistica - mente significativa para la tecnica de hipoclorito de sodio/ grupo control (p=.001). La utilizacion de hipoclorito de sodio ayuda a mejorar la adhesion de los brackets en la superficie del esmalte.

OBJECTIVE: To identify the prevalence and factors associated with cervical human papillomavirus infection in women with systemic lupus erythematosus METHODS: This cross-sectional study collected traditional and systemic lupus erythematosus-related disease risk factors, including conventional and biologic therapies. A gynecological evaluation and cervical cytology screen were performed. Human papillomavirus detection and genotyping were undertaken by PCR and linear array assay. RESULTS: A total of 148 patients were included, with a mean age and disease duration of 42.5±11.8 years and 9.7±5.3 years, respectively. The prevalence of squamous intraepithelial lesions was 6.8%. The prevalence of human papillomavirus infection was 29%, with human papillomavirus subtype 59 being the most frequent. Patients with human papillomavirus were younger than those without the infection (38.2±11.2 vs. 44.2±11.5 years, respectively; p = 0.05), and patients with the virus had higher daily prednisone doses (12.8±6.8 vs. 9.7±6.7 mg, respectively; p = 0.01) and cumulative glucocorticoid doses (14.2±9.8 vs. 9.7±7.3 g, respectively; p = 0.005) compared with patients without. Patients with human papillomavirus infection more frequently received rituximab than those without (20.9% vs. 8.5%, respectively; p = 0.03). In the multivariate analysis, only the cumulative glucocorticoid dose was associated with human papillomavirus infection. CONCLUSIONS: The cumulative glucocorticoid dose may increase the risk of human papillomavirus infection. Although rituximab administration was more frequent in patients with human papillomavirus infection, no association was found. Screening for human papillomavirus infection is recommended in women with systemic lupus erythematosus.